Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain

NCT01315886 is registered in ClinicalTrials.gov with Orexo AB as lead sponsor.

NCT NCT01315886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01315886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain
Lead sponsor
Orexo AB
Phase
Phase 4
Overall status
Terminated
Start date
February 21, 2011
Completion date
December 7, 2011
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain